Weekly NADAC archive
Every weekly executive brief is preserved as a dated snapshot so the editorial narrative, Top 10 movers, and supporting summaries stay consistent over time.
Archived editions
Latest edition count: 3. Use the latest page for the current brief and these dated pages for historical context.
Pricing pressure broadened across endocrine and respiratory products as a small set of high-volume therapies drove the week’s largest shifts.
The latest release shows a concentrated pattern of movement rather than a broad market-wide reset. Most of the week’s largest increases were concentrated in a narrow group of high-exposure products, while relief remained more fragmented across lower-cost oral therapies.
Respiratory and cardiovascular names led a narrower repricing week as supplier-level changes remained concentrated rather than market-wide.
The prior release showed a more selective set of price resets, with supplier-specific moves driving most of the measured impact. Relief showed up in several established cardiovascular therapies, but broad deflation still did not develop across the full market.
Pricing pressure remained focused in a smaller set of anti-infective and endocrine products while broad supplier dispersion stayed relatively stable.
This release leaned more heavily on product-specific resets than on broad-based category repricing. Anti-infective moves stood out in percentage terms, but endocrine names still accounted for the largest weighted pressure across higher-volume products.